{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:31:10Z","timestamp":1771014670717,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[1995,1,1]],"date-time":"1995-01-01T00:00:00Z","timestamp":788918400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1995,1]]},"DOI":"10.1007\/s002800050253","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T04:03:26Z","timestamp":1030248206000},"page":"397-402","source":"Crossref","is-referenced-by-count":9,"title":["A Phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors"],"prefix":"10.1007","volume":"35","author":[{"given":"Geoffrey R.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinee","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lon S.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gladys I.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard A.","family":"Burris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Fields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla","family":"VanDenBerg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D.","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"50350397280_CR1","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1073\/pnas.81.7.2232","volume":"81","author":"DA Carson","year":"1984","unstructured":"Carson DA, Wasson DB, Beutler E (1984) Antileukemic and immunosuppressive activity of 2-chloro-2\u2032-deoxyadenosine. Proc Nat1 Acad Sci USA 81: 2232","journal-title":"Proc Nat1 Acad Sci USA"},{"issue":"1","key":"50350397280_CR2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/10428199109103391","volume":"5","author":"BD Cheson","year":"1991","unstructured":"Cheson BD, Vena DA, Sorenson JM, Fallavollita A (1991) Current status of U.S. clinical trials in chronic lymphocytic leukemia. Leuk Lymph 5 [Supp1]: 119","journal-title":"Leuk Lymph"},{"key":"50350397280_CR3","first-page":"223a","volume":"68","author":"MR Grever","year":"1986","unstructured":"Grever MR, Coltman CA Jr, Files JC, et al (1986) Fludarabine monophosphate in chronic lymphocytic leukemia. Blood 68 [Suppl]: 223a","journal-title":"Blood"},{"key":"50350397280_CR4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/bjc.1993.24","volume":"67","author":"T Hickish","year":"1993","unstructured":"Hickish T, Serafinowski P, Cunningham D, Oza A, Dorland E, Judson I, Millar BC, Lister TA, Roldan A (1993) 2-Chloro-deoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer 67: 139","journal-title":"Br J Cancer"},{"key":"50350397280_CR5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1089\/cdd.1986.3.115","volume":"3","author":"JJ Hutton","year":"1986","unstructured":"Hutton JJ, Von Hoff DD (1986) Cytotoxicity of 2-chlorodeoxyadenosine in a human tumor colony-forming assay. Cancer Drug Deliv 3: 115","journal-title":"Cancer Drug Deliv"},{"key":"50350397280_CR6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.1993.11.4.679","volume":"11","author":"G Juliusson","year":"1993","unstructured":"Juliusson G, Liliemark J (1993) High complete remission rate from 2-chloro-2\u2032-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 11: 679","journal-title":"J Clin Oncol"},{"key":"50350397280_CR7","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1056\/NEJM199210083271504","volume":"327","author":"G Juliusson","year":"1992","unstructured":"Juliusson G, Elmhorn-Rosenborg A, Liliemark J (1992) Response to 2-chlorodeoxyadenosine in patients with B cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 327: 1056","journal-title":"N Engl J Med"},{"key":"50350397280_CR8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1200\/JCO.1992.10.3.371","volume":"10","author":"AC Kay","year":"1992","unstructured":"Kay AC, Saven A, Carrera CJ, Carson DA, Thurston D, Beutler E, Piro LD (1992) 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 10: 371","journal-title":"J Clin Oncol"},{"key":"50350397280_CR9","first-page":"49","volume":"17","author":"MJ Keating","year":"1990","unstructured":"Keating MJ (1990) Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin Oncol 17 [Suppl]: 49","journal-title":"Semin Oncol"},{"key":"50350397280_CR10","first-page":"5570","volume":"51","author":"J Liliemark","year":"1991","unstructured":"Liliemark J, Juliusson G (1991) On the pharmacokinetics of 2-chloro-2\u2032-deoxyadenosine in humans. Cancer Res 51: 5570","journal-title":"Cancer Res"},{"key":"50350397280_CR11","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1200\/JCO.1992.10.10.1514","volume":"10","author":"J Liliemark","year":"1992","unstructured":"Liliemark J, Albertioni F, Hassan M, Juliusson G (1992) On the bioavailability of oral and subcutaneous 2-chloro-2\u2032-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 10: 1514","journal-title":"J Clin Oncol"},{"key":"50350397280_CR12","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.V72.3.1069.bloodjournal7231069","volume":"72","author":"LD Piro","year":"1988","unstructured":"Piro LD, Carrera CJ, Beutler E, Carson DA (1988) 2-Chloro-deoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 72: 1069","journal-title":"Blood"},{"key":"50350397280_CR13","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199004193221605","volume":"322","author":"LD Piro","year":"1990","unstructured":"Piro LD, Carrera CJ, Carson DA, Beutler E (1990) Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322: 1117","journal-title":"N Engl J Med"},{"key":"50350397280_CR14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.1992.10.3.364","volume":"10","author":"V Santana","year":"1992","unstructured":"Santana V, Mirro J, Kearns C, Schell M, Crom W, Blakley L (1992) 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 10: 364","journal-title":"J Clin Oncol"},{"key":"50350397280_CR15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/10428199309149111","volume":"10","author":"A Saven","year":"1993","unstructured":"Saven A, Piro LD (1993) 2-Chlorodeoxyadenosine: a new nucleoside agent effective in the treatment of lymphoid malignancies. Leuk Lymph 10 [Suppl]: 43","journal-title":"Leuk Lymph"},{"key":"50350397280_CR16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7326\/0003-4819-119-4-199308150-00005","volume":"119","author":"A Saven","year":"1993","unstructured":"Saven A, Piro LD (1993) Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2\u2032-deoxycoformycin. Ann Intern Med 119: 278","journal-title":"Ann Intern Med"},{"key":"50350397280_CR17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V80.3.587.587","volume":"80","author":"A Saven","year":"1992","unstructured":"Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD (1992) 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80: 587","journal-title":"Blood"},{"key":"50350397280_CR18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1172\/JCI111710","volume":"75","author":"S Seto","year":"1985","unstructured":"Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA (1985) Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to non-dividing human lymphocytes. J Clin Invest 75: 377","journal-title":"J Clin Invest"},{"key":"50350397280_CR19","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood.V80.9.2203.2203","volume":"80","author":"MS Tallman","year":"1992","unstructured":"Tallman MS, Hakimian D, Variakojis D, Koslow D, Sisney GA, Rademaker AW, Rose E, Kaul K (1992) A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 80: 2203","journal-title":"Blood"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s002800050253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s002800050253\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s002800050253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T11:38:20Z","timestamp":1578397100000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s002800050253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,1]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1995,1]]}},"alternative-id":["50350397280"],"URL":"https:\/\/doi.org\/10.1007\/s002800050253","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,1]]}}}